Barbiturates

thumb|class=skin-invert-image|Barbituric acid, the [[parent structure of all barbiturates]]

Phenobarbital, also known as phenobarbitone, sold under the brand name Luminal among others, is a medication of the barbiturate type. It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries. In the developed world, it is commonly used to treat seizures in young children, while other medications are generally used in older children and adults. It is also used for veterinary purposes.

Pentobarbital (US) or pentobarbitone (British and Australian) is a short-acting barbiturate typically used as a sedative, a preanesthetic, and to control convulsions in emergencies. It can also be used for short-term treatment of insomnia but has been largely replaced by the benzodiazepine family of drugs.

chemical compound

Amobarbital (formerly known as amylobarbitone or sodium amytal as the soluble sodium salt) is a drug that is a barbiturate derivative. It has sedative-hypnotic properties. It is a white crystalline powder with no odor and a slightly bitter taste. It was first synthesized in Germany in 1923. It is considered a short to intermediate acting barbiturate.

Barbital (or barbitone), sold under the brand names Veronal for the pure acid and Medinal for the sodium salt, was the first commercially available barbiturate. It was used as a sleeping aid (hypnotic) from 1903 until the mid-1950s. The chemical names for barbital are diethylmalonyl urea or diethylbarbituric acid; hence, the sodium salt is known also as sodium diethylbarbiturate.

Secobarbital, sold under the brand name Seconal among others, is a short-acting barbiturate drug originally used for the treatment of insomnia. It was patented by Eli Lilly and Company in 1934 in the United States. It possesses anesthetic, anticonvulsant, anxiolytic, sedative, and hypnotic properties. In the United Kingdom, it was known as quinalbarbitone. Secobarbital is considered to be an obsolete sedative-hypnotic (sleeping pill) and has largely been replaced by the benzodiazepine family. It was widely abused, known on the street as "red devils" or "reds." Among barbiturates, secobarbital

Methylphenobarbital (INN), also known as mephobarbital (USAN, JAN) and mephobarbitone (BAN), marketed under brand names such as Mebaral, Mephyltaletten, Phemiton, and Prominal, is a drug which is a barbiturate derivative and is used primarily as an anticonvulsant, but also as a sedative and anxiolytic. It is the N-methylated analogue of phenobarbital and has similar indications, therapeutic value, and tolerability.

Allobarbital, also known as allobarbitone and branded as Dial, Cibalgine (in combination with aminophenazone), or Dial-Ciba (in combination with ethyl carbamate), is a barbiturate derivative invented in 1912 by Ernst Preiswerk and Ernst Grether working for CIBA. It was used primarily as an anticonvulsant although it has now largely been replaced by newer drugs with improved safety profiles. Other uses for allobarbital included as an adjutant to boost the activity of analgesic drugs, and use in the treatment of insomnia and anxiety.

Methohexital or methohexitone (marketed under the brand names Brevital and Brietal) is a barbiturate derivative. It is classified as short-acting, and has a rapid onset of action. It is similar in its effects to sodium thiopental, a drug it competed with in the market for anesthetics.

Cyclobarbital, cyclobarbitol or cyclobarbitone is a barbiturate derivative developed in the early 1970s in the Soviet Union.

Butobarbital, also called butobarbitone or butethal, Soneryl, and Neonal, is a hypnotic drug which is a barbiturate derivative. It was developed by Poulenc Brothers (now part of Sanofi) in 1921.

Hexobarbital or hexobarbitone, sold both in acid and sodium salt forms as Citopan, Evipan, and Tobinal, is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s and 1950s as an agent for inducing anesthesia for surgery, as well as a rapid-acting, short-lasting hypnotic for general use, and has a relatively fast onset of effects and short duration of action. Modern barbiturates (such as Thiopental) have largely supplanted the use of hexobarbital as an anesthetic, as they allow for better control of the depth of anesthesia. Hexobarbital is still used in some sci

Aprobarbital (or aprobarbitone), sold under the brand names Oramon, Somnifaine, and Allonal, is a barbiturate derivative invented in the 1920s by Ernst Preiswerk. It has sedative, hypnotic, and anticonvulsant properties, and was used primarily for the treatment of insomnia. Aprobarbital was never as widely used as more common barbiturate derivatives such as phenobarbital and is now rarely prescribed. It has been largely replaced by newer drugs with a better safety margin.

medical condition

Alphenal, also known as 5-allyl-5-phenylbarbituric acid, is a barbiturate derivative developed in the 1920s. It has primarily anticonvulsant properties and was used occasionally for the treatment of epilepsy or convulsions, although not as commonly as better known barbiturates such as phenobarbital.

Butalbital is a barbiturate with an intermediate duration of action. Butalbital is often combined with other medications, such as paracetamol (acetaminophen) (as butalbital/acetaminophen) or aspirin, for the treatment of pain and headache. The various formulations combined with codeine are FDA-approved for the treatment of tension headaches. Butalbital has the same chemical formula as talbutal but a different structure—namely, 5-allyl-5-isobutylbarbituric acid.

Vinylbital, also known as butylvinal, is a sedative hypnotic drug which is a barbiturate derivative. It was developed by Aktiebolaget Pharmacia in the 1950s.

Butabarbital (brand name Butisol) is a prescription barbiturate sleep aid and anxiety medication. Butabarbital has a particularly fast onset of effects and short duration of action compared to other barbiturates, which makes it useful for certain applications such as treating severe insomnia, relieving general anxiety and relieving anxiety before surgical procedures; however it is also relatively dangerous particularly when combined with alcohol, and so is now rarely used, although it is still prescribed in some Eastern European and South American countries. Its intermediate duration of action

Narcobarbital (Pronarcon) is a barbiturate derivative developed in 1932 by Carl Heinrich Friedrich Boedecker and Heinrich Gruber Schoneberg, assignors to the firm J. D. Riedel-E. de Haën AG, Berlin, Germany. Later, in 1937, may, was patented in United States. It is an N-methylated derivative of propallylonal and has similar sedative effects. It is still used in veterinary medicine for inducing surgical anaesthesia.

Vinbarbital is a hypnotic drug which is a barbiturate derivative. It was developed by Sharp and Dohme in 1939.

Benzobarbital (Benzonal) is a barbiturate derivative. It has anticonvulsant effects and has been used for the treatment of epilepsy.

Heptabarb (INN; Eudan, Medapan, Medomin, Noctyn), also known as heptabarbitone (BAN) or heptabarbital, is a sedative and hypnotic drug of the barbiturate family. It was used in Europe for the treatment of insomnia from the 1950s onwards, but has since been discontinued.

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine. It was introduced in 1965. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results" had not yet been confirmed nor denied in controlled trials.

Proxibarbital (Ipronal) is a barbiturate derivative synthesized in 1956 in Poland by Bogusław Bobrański. It has anti-anxiety and sedative properties and is, in contrast to most barbiturates, almost without hypnotic action. It was used as a sedative and anti-anxiety drug. It was also used in the treatment of migraine headaches in a similar manner to butalbital. It was a prescription drug available in Poland from the 1950s to the 1990s under trade name Ipronal.

Reposal is a barbiturate derivative invented in the 1960s in Denmark. It has sedative, hypnotic and anticonvulsant properties, and was used primarily for the treatment of insomnia.

Ethallobarbital (brand names Dormin, Dumex, Dormitiv, Dorval), also known as ethallymal and 5-allyl-5-ethylbarbituric acid, is an allyl-substituted barbiturate described as a sedative/hypnotic. It was first synthesized in 1927.

Talbutal (Lotusate) is a barbiturate with a short to intermediate duration of action. It is a structural isomer of butalbital. Talbutal is a schedule III drug in the U.S.

Metharbital was patented in 1905 by Emil Fischer working for Merck. It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy. It has similar properties to phenobarbital.

Propylbarbital (Propal, Propanal, Proponal), also known as 5,5-dipropylbarbituric acid, is a barbiturate derivative used as a hypnotic drug.

Nealbarbital (Censedal) is a barbiturate derivative developed by Aktiebolaget Pharmacia in the 1950s. It has sedative and hypnotic effects, and was used for the treatment of insomnia.

Phetharbital (phenetharbital) is a barbiturate derivative. It has anticonvulsant effects and relatively weak sedative action, and is considered to have a low abuse potential.

Enallylpropymal (Narconumal) is a barbiturate derivative developed by Hoffman la Roche in the 1930s. It has sedative and hypnotic effects and is considered to have a moderate abuse potential.

Febarbamate (INN; Solium, Tymium), also known as phenobamate, is an anxiolytic and tranquilizer of the barbiturate and carbamate families which is used in Europe by itself and as part of a combination drug formulation called tetrabamate.

Crotylbarbital (Mepertan, Kalipnon, Barotal), also known as crotarbital, is a barbiturate derivative developed by Eli Lilly in the 1930s. It has sedative and hypnotic effects, and was used for the treatment of insomnia until it was replaced by newer alternative drugs with fewer side effects and lower risk of overdose.

Heptobarbital (Rutonal), also known as phenylmethylbarbituric acid is a barbiturate derivative. It has often been confused with methylphenobarbital because both drugs contain a methylphenyl moiety and are overall very similar in structure.

Brallobarbital was a barbiturate developed in the 1920s. It has sedative and hypnotic properties, and was used for the treatment of insomnia. Brallobarbital was primarily sold as part of a combination product called Vesparax, composed of 150 mg secobarbital, 50 mg brallobarbital and 50 mg hydroxyzine. The long half-life of this combination of drugs tended to cause a hangover effect the next day, and Vesparax fell into disuse once newer drugs with lesser side effects had been developed. Vesparax reportedly was the drug that musician Jimi Hendrix supposedly overdosed on and led to

Tetrabarbital (INN; Butysal, Butysedal, Tetramal) is a barbiturate derivative used as a hypnotic.

Spirobarbital is a barbiturate derivative developed by Eli Lilly in the 1940s. It has hypnotic and sedative effects, and has a moderate potential for abuse.

Eterobarb (Antilon) is a barbiturate derivative. It has mainly anticonvulsant action with less sedative effects than the closely related compound phenobarbital. It saw reasonable success in clinical trials, but is not in widespread medical use.

Carbubarb (carbubarbital, trade name Nogexan) is a carbamate-substituted barbiturate derivative, which has sedative effects.

Benzylbutylbarbiturate ('5-benzyl-5-n-butylbarbituric acid') is a rare example of a barbiturate designer drug, possibly the only such compound encountered in recent years.

Butallylonal is a barbiturate derivative invented in the 1920s. It has sedative properties, and was used primarily as an anaesthetic in veterinary medicine. Butallylonal is considered similar in effects to pentobarbital but is longer in action, being considered an intermediate-acting barbiturate rather than short-acting.

chemical compound

Bucolome (Paramidine) is a barbiturate derivative. Unlike most barbiturates it does not have any significant sedative or hypnotic effects, but instead acts as an analgesic and antiinflammatory. It also acts as a CYP2C9 inhibitor and reduces the metabolism of several commonly used drugs, which makes it useful for potentiating or extending the duration of action of those drugs, or reducing the production of unwanted metabolites.

Sigmodal (Rectidon) is a barbiturate derivative. It has sedative, hypnotic and anticonvulsant properties, and was used in surgical anaesthesia in the 1950s, and frequently appeared in drug mixtures in the 60s.

Cyclopentobarbital sodium (Cyclopal, Dormisan) is a barbiturate derivative invented in the 1940s. It has sedative and anticonvulsant properties, and was used primarily as an anaesthetic in veterinary medicine. Cyclopal is considered similar in effects to phenobarbital but lasts almost three times as long, and is considered a long-acting barbiturate with a fairly slow onset of action.

Probarbital (trade names Ipral, Vasalgin) is a barbiturate derivative invented in the 1920s. It has sedative, hypnotic and anticonvulsant properties.

Difebarbamate (INN) is a tranquilizer of the barbiturate and carbamate families which is used in Europe as a component of a combination drug formulation referred to as tetrabamate (Atrium, Sevrium).

Brophebarbital is a barbiturate derivative. It has sedative and hypnotic effects and is considered to have a moderate abuse potential.

Propallylonal (trade names Nostal, Quietal, Ibomal) is a barbiturate derivative invented in the 1920s. It has sedative, hypnotic and anticonvulsant properties, and is still rarely prescribed as a sleeping medication in some Eastern-European countries.

Hexethal (Ortal) is a barbiturate derivative invented in the 1940s. It has sedative, anxiolytic, muscle relaxant, and anticonvulsant properties, and was used primarily as an anaesthetic in veterinary medicine.

Zoliflodacin, sold under the brand name Nuzolvence, is an antibiotic used for the treatment of antibiotic-resistant Neisseria gonorrhoeae (gonorrhea). Zoliflodacin is being developed as part of a public-private partnership between Innoviva Specialty Therapeutics and the Global Antibiotic Research & Development Partnership (GARDP). Zoliflodacin is taken by mouth.

Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth.

drug dependence that involves the continued use of barbiturates despite problems related to use of the substance

thumb|Corvalol

Prazitone (, ; developmental code name AGN-511) is a barbiturate derivative described as an antidepressant which was developed in the 1960s. Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant. The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.